Glucocorticoid-induced Hyperlipidemia

Cyclosporin A-Induced Hyperlipidemia

Cyclosporin A (CsA) is an immunosuppressant drug widely used in organ transplant recipients and patients with auto-immune disorders. Long-term treatment with CsA is associated with hyperlipidemia and an increased risk of atherosclerosis. The mechanisms by which cyclosporin A causes hyperlipidemia are unclear. Cell and animal studies have pointed to various mechanisms that may mediate CsA-induce...

Glucocorticoid-induced osteoporosis

Corticosteroid-induced osteoporosis is the most common form of secondary osteoporosis and the first cause in young people. Bone loss and increased rate of fractures occur early after the initiation of corticosteroid therapy, and are then related to dosage and treatment duration. The increase in fracture risk is not fully assessed by bone mineral density measurements, as it is also related to al...

Glucocorticoid-induced osteoporosis.

Glucocorticoid drugs interact with bone metabolism at many levels, but their principal action is to reduce osteoblast number and bone matrix synthesis. Virtually all patients receiving glucocorticoids in doses above 5 mg per day lose bone, the amount lost being dependent on the cumulative steroid dose. The risk of fracture is also related to the individual's initial bone density, which in turn ...

Glucocorticoid-induced osteoporosis.

Glucocorticoid-induced osteoporosis is one of the most important side-effects of glucocorticoid use, leading to an increased fracture risk. In this review, recent advances in the understanding of the mechanisms of glucocorticoid-induced osteoporosis are summarised. Methods to identify persons at risk for fractures are discussed, as well as the new ACR recommendations for the prevention and trea...

Glucocorticoid-induced Osteoporosis